This study is currently not recruiting participants.

A Three-Part Phase 3 Randomized Double Blind Placebo Controlled Four-Arm Discontinuation Study to Evaluate the Efficacy and Safety of Subcutaneous Injections of BMN 165 Self Administered by Adults With Phenylketonuria

Investigating Medication for Phenylketonuria (PKU)

Not Recruiting
18 years - 70 years
All
Phase N/A

Brief description of study.

The purpose of this research study is to learn if a drug called BMN 165 can help people with PKU.

Detailed description of study

The purpose of this research study is to learn if a drug called BMN 165 can help people with PKU.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Phenylketonuria
  • Age: 18 years - 70 years
  • Gender: All

This study investigates the effects of an investigational medication on individuals with phenylketonuria (PKU), a rare genetic disorder where the body cannot break down an amino acid called phenylalanine. This can lead to health problems if not managed properly.

Participants in the study will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine. The study will monitor the participants' response to the treatment.

  • Who can participate: Participants aged 18 to 65 with a confirmed diagnosis of phenylketonuria (PKU) may be eligible for the study. Key eligibility factors include stable health status and adherence to a controlled diet.
  • Study details: Participants will receive either the investigational medication or a placebo. The study will monitor the participants' response to the treatment.
Updated on 19 Feb 2024. Study ID: 1308025764

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team